Breaking News Instant updates and real-time market news.

STML

Stemline

$12.92

-0.71 (-5.21%)

17:02
03/18/19
03/18
17:02
03/18/19
17:02

Stemline sees positive physician feedback in all categories, says Piper Jaffray

Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $23 price target on Stemline, saying his conversations with the management after the company's Q4 results reflected "very positive" feedback from physicians with patient enrollments "in all major sales territories." The analyst believes that the company's Elzonris sales may reach $1.9M, and "expansion opportunities in subsets of CMML and MF" could take shape by mid-2019.

STML Stemline
$12.92

-0.71 (-5.21%)

12/26/18
HCWC
12/26/18
NO CHANGE
Target $38
HCWC
Buy
Stemline boxed warning shouldn't deter use of Elzonris, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju noted that the FDA approved Stemline's Elzonris two months before the drug's PDUFA date, which he sees as evidence of the FDA's acknowledgement of the urgent need for blastic plasmacytoid dendritic cell neoplasm patients given this is the first drug approved in this indication. He also believes, based on his talks with knowledge leaders at the American Society of Hematology meeting, that the boxed warning given to Elzonris should not deter physicians from getting BPDCN patients on the drug, Selvaraju tells investors. He maintains a Buy rating and $38 price target on Stemline shares.
02/06/19
PIPR
02/06/19
NO CHANGE
Target $23
PIPR
Overweight
Stemline price target lowered to $23 from $30 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro lowered his price target for Stemline Therapeutics to $23 to reflect reduced 2019 Elzonris estimates. Given the shortened Q1 selling period and expectations that early use will be heavily weighted towards blastic plasmacytoid dendritic cell neoplasm, who receive fewer cycles of therapy, the analyst reduced his 2019 Elzonris estimates. However, he believes the drug's long-term opportunity is intact. Catanzaro continues to view Stemline shares as undervalued and thinks the now approved U.S. BPDCN label is a $250M opportunity. He keeps an Overweight rating on Stemline Therapeutics.
03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
03/11/19
PIPR
03/11/19
NO CHANGE
Target $23
PIPR
Overweight
Stemline's Elzonris to become BPDCN standard of care, says Piper Jaffray
After speaking with a key opinion leader, Piper Jaffray analyst Joseph Catanzaro says he continues to have no doubt that Stemline Therapeutics' Elzonris will become standard of care for blastic plasmacytoid dendritic cell neoplasm. The analyst remains "very comfortable" with his 500 patient annual U.S. incidence estimate. He models for $300M in peak U.S. sales for Elzonris and maintains an Overweight rating on Stemline with a $23 price target.

TODAY'S FREE FLY STORIES

MDR

McDermott

$6.19

-0.64 (-9.38%)

15:34
05/23/19
05/23
15:34
05/23/19
15:34
Hot Stocks
McDermott reaffirms schedule for Freeport LNG project »

McDermott reaffirmed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

INTU

Intuit

$241.15

-6.37 (-2.57%)

15:34
05/23/19
05/23
15:34
05/23/19
15:34
Options
Intuit options imply 5.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AMZN

Amazon.com

$1,811.20

-46.54 (-2.51%)

, GOOG

Alphabet

$1,134.97

-15.53 (-1.35%)

15:31
05/23/19
05/23
15:31
05/23/19
15:31
Periodicals
Amazon-backed self-driving unicorn Aurora buys lidar maker, Forbes says »

According to Alan Ohnsman…

AMZN

Amazon.com

$1,811.20

-46.54 (-2.51%)

GOOG

Alphabet

$1,134.97

-15.53 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

  • 19

    Jun

  • 25

    Jun

  • 27

    Oct

WPG

Washington Prime

$4.48

0.02 (0.45%)

15:20
05/23/19
05/23
15:20
05/23/19
15:20
Options
Notable put buy in Washington Prime »

Notable put buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

SPLK

Splunk

$128.52

-7.28 (-5.36%)

15:19
05/23/19
05/23
15:19
05/23/19
15:19
Options
Splunk options imply 9.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 13

    Jun

  • 09

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
05/23/19
05/23
15:17
05/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$47.50

-1.605 (-3.27%)

15:16
05/23/19
05/23
15:16
05/23/19
15:16
Periodicals
Breaking Periodicals news story on Canada Goose »

Hedgeye adds Canada Goose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
05/23/19
05/23
15:16
05/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTE

DTE Energy

$128.90

0.6 (0.47%)

15:14
05/23/19
05/23
15:14
05/23/19
15:14
Hot Stocks
DTE Energy officer Mark Stiers sells almost $1.3M in company shares »

DTE Energy officer Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 12

    Jun

DNR

Denbury Resources

$1.57

-0.15 (-8.72%)

15:10
05/23/19
05/23
15:10
05/23/19
15:10
Options
Denbury Resources draws call buying as shares probe 2019 lows »

Denbury Resources draws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

15:10
05/23/19
05/23
15:10
05/23/19
15:10
General news
Treasury Market Summary »

Treasury Market Summary:…

WETF

WisdomTree

$6.13

-0.305 (-4.74%)

15:06
05/23/19
05/23
15:06
05/23/19
15:06
Hot Stocks
WisdomTree CEO Jonathan Steinberg buys over $496K in shares »

WisdomTree CEO Jonathan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

HPQ

HP Inc.

$19.16

-0.13 (-0.67%)

15:04
05/23/19
05/23
15:04
05/23/19
15:04
Options
HP Inc. options imply 7.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

TMUS

T-Mobile

$75.93

-0.42 (-0.55%)

, S

Sprint

$6.91

0.22 (3.29%)

15:02
05/23/19
05/23
15:02
05/23/19
15:02
Hot Stocks
Pennsylvania PUC approves application related to proposed Sprint/T-Mobile merger »

The Pennsylvania Public…

TMUS

T-Mobile

$75.93

-0.42 (-0.55%)

S

Sprint

$6.91

0.22 (3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

MAXR

Maxar Technologies

$7.93

0.78 (10.91%)

14:59
05/23/19
05/23
14:59
05/23/19
14:59
Hot Stocks
Breaking Hot Stocks news story on Maxar Technologies »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$666.60

-39.45 (-5.59%)

14:55
05/23/19
05/23
14:55
05/23/19
14:55
Hot Stocks
Chipotle disagrees with downgrade, sees no major impact from African swine fever »

After BMO Capital analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

MAXR

Maxar Technologies

$7.93

0.78 (10.91%)

14:55
05/23/19
05/23
14:55
05/23/19
14:55
Hot Stocks
Maxar selected to build, fly first element of NASA's Lunar Gateway »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLF

Herbalife Nutrition

$43.33

-1.03 (-2.32%)

14:55
05/23/19
05/23
14:55
05/23/19
14:55
Options
Herbalife put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRNT

Verint

$54.60

-6.61 (-10.80%)

14:54
05/23/19
05/23
14:54
05/23/19
14:54
Recommendations
Verint analyst commentary  »

Oppenheimer says buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 20

    Jun

ADSK

Autodesk

$168.15

-5.96 (-3.42%)

14:49
05/23/19
05/23
14:49
05/23/19
14:49
Options
Autodesk options imply 8.6% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

GWR

Genesee & Wyoming

$85.51

-0.55 (-0.64%)

, BX

Blackstone

$40.81

-0.89 (-2.13%)

14:48
05/23/19
05/23
14:48
05/23/19
14:48
Periodicals
Genesee & Wyoming pursued by Blackstone, Brookfield, others, Bloomberg says »

Blackstone (BX),…

GWR

Genesee & Wyoming

$85.51

-0.55 (-0.64%)

BX

Blackstone

$40.81

-0.89 (-2.13%)

BAM

Brookfield

$46.47

-0.33 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 19

    Jun

  • 08

    Aug

  • 13

    Nov

NXPI

NXP Semiconductors

$90.85

-2.79 (-2.98%)

14:45
05/23/19
05/23
14:45
05/23/19
14:45
Options
NXP Semiconductors call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 29

    May

  • 13

    Jun

FE

FirstEnergy

$42.94

0.31 (0.73%)

14:36
05/23/19
05/23
14:36
05/23/19
14:36
Periodicals
Breaking Periodicals news story on FirstEnergy »

Ohio advances bill that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$202.83

-6.34 (-3.03%)

14:35
05/23/19
05/23
14:35
05/23/19
14:35
Hot Stocks
Huntington Ingalls VP William Ermatinger sells almost $400K in company shares »

Huntington Ingalls VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

QRVO

Qorvo

$59.38

-0.83 (-1.38%)

14:35
05/23/19
05/23
14:35
05/23/19
14:35
Options
Qorvo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.